tbuckley/cabot-search huggingface dataset:
A Pragmatic Approach to Determine Components of Optimal Screening Mammography Practice
Authors: Elizabeth S. Burnside, Edward A. Sickles, Stephen W. Duffy
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dendritic Cells as Immunologic Adjuvants for the Treatment of Cancer
Authors: Jan Baggers, Gudrun Ratzinger, James W. Young
Journal: Journal of Clinical Oncology (2000)

Article Tools EDITORIAL Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.23.3879 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11099316 Dendritic Cells as Immunologic Adjuvants for the Treatment of Cancer Jan Baggers, MDxJan BaggersSearch for articles by this author , Gudrun Ratzinger, MDxGudrun RatzingerSearch for articles by this author , James W. Young, MDxJames W. YoungSearch for articles by this author Show More Memorial Sloan-Kettering Cancer Center New York, NY https://doi.org/10.1200/JCO.2000.18.23.3879 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Smoking Behavior and Healthcare Expenditure in the United States, 1992–2009: Panel Data Estimates
Authors: James Lightwood, Stanton A. Glantz
Journal: PLoS Medicine (2016)

Background Reductions in smoking in Arizona and California have been shown to be associated with reduced per capita healthcare expenditures in these states compared to control populations in the rest of the US. This paper extends that analysis to all states and estimates changes in healthcare expenditure attributable to changes in aggregate measures of smoking behavior in all states. Methods and Findings State per capita healthcare expenditure is modeled as a function of current smoking prevalence, mean cigarette consumption per smoker, other demographic and economic factors, and cross-sectional time trends using a fixed effects panel data regression on annual time series data for each the 50 states and the District of Columbia for the years 1992 through 2009. We found that 1% relative reductions in current smoking prevalence and mean packs smoked per current smoker are associated with 0.118% (standard error [SE] 0.0259%, p < 0.001) and 0.108% (SE 0.0253%, p < 0.001) reductions in per capita healthcare expenditure (elasticities). The results of this study are subject to the limitations of analysis of aggregate observational data, particularly that a study of this nature that uses aggregate data and a relatively small sample size cannot, by itself, establish a causal connection between smoking behavior and healthcare costs. Historical regional variations in smoking behavior (including those due to the effects of state tobacco control programs, smoking restrictions, and differences in taxation) are associated with substantial differences in per capita healthcare expenditures across the United States. Those regions (and the states in them) that have lower smoking have substantially lower medical costs. Likewise, those that have higher smoking have higher medical costs. Sensitivity analysis confirmed that these results are robust. Conclusions Changes in healthcare expenditure appear quickly after changes in smoking behavior. A 10% relative drop in smoking in every state is predicted to be followed by an expected $63 billion reduction (in 2012 US dollars) in healthcare expenditure the next year. State and national policies that reduce smoking should be part of short term healthcare cost containment.
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Authors: Vasileios Askoxylakis, Gino B. Ferraro, David P. Kodack, Mark Badeaux, Ram C. Shankaraiah, Giorgio Seano, Jonas Kloepper, Trupti Vardam, John D. Martin, Kamila Naxerova, Divya Bezwada, Xiaolong Qi, Martin K. Selig, Elena Brachtel, Dan G. Duda, Peigen Huang, Dai Fukumura, Jeffrey A. Engelman, Rakesh K. Jain
Journal: JNCI Journal of the National Cancer Institute (2015)

Central nervous system (CNS) metastases represent a major problem in the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer because of the disappointing efficacy of HER2-targeted therapies against brain lesions. The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has shown efficacy in trastuzumab-resistant systemic breast cancer. Here, we tested the hypothesis that T-DM1 could overcome trastuzumab resistance in murine models of brain metastases. We treated female nude mice bearing BT474 or MDA-MB-361 brain metastases (n = 9–11 per group) or cancer cells grown in organotypic brain slice cultures with trastuzumab or T-DM1 at equivalent or equipotent doses. Using intravital imaging, molecular techniques and histological analysis we determined tumor growth, mouse survival, cancer cell apoptosis and proliferation, tumor drug distribution, and HER2 signaling. Data were analyzed with one-way analysis of variance (ANOVA), Kaplan-Meier analysis, and Coefficient of Determination. All statistical tests were two-sided. T-DM1 delayed the growth of HER2-positive breast cancer brain metastases compared with trastuzumab. These findings were consistent between HER2-driven and PI3K-driven tumors. The activity of T-DM1 resulted in a survival benefit (median survival for BT474 tumors: 28 days for trastuzumab vs 112 days for T-DM1, hazard ratio = 6.2, 95% confidence interval = 6.1 to 85.84, P < .001). No difference in drug distribution or HER2-signaling was revealed between the two groups. However, T-DM1 led to a statistically significant increase in tumor cell apoptosis (one-way ANOVA for ApopTag, P < .001), which was associated with mitotic catastrophe. T-DM1 can overcome resistance to trastuzumab therapy in HER2-driven or PI3K-driven breast cancer brain lesions due to the cytotoxicity of the DM1 component. Clinical investigation of T-DM1 for patients with CNS metastases from HER2-positive breast cancer is warranted.
Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo
Authors: Junliang Pan, Thanh Theresa Dinh, Anusha Rajaraman, Mike Lee, Alexander Scholz, Cathrin J. Czupalla, Helena Kiefel, Li Zhu, Lijun Xia, John Morser, Haiyan Jiang, Laura Santambrogio, Eugene C. Butcher
Journal: Blood (2016)
Abstract 1575: Serum circulating miR–Test application: Standardized protocol for miR–Test clinical application
Authors: Francesca Montani, Matteo Marzi, Fabio Dezi, Elisa Dama, Rose Mary Carletti, Giulia Veronesi, Francesco Nicassio, Pier Paolo Di Fiore, Fabrizio Bianchi
Journal: Cancer Research (2015)

Abstract Lung cancer is leading cause of cancer death worldwide. Being lung cancer asymptomatic in its early stages, the majority of patients are diagnosed with advanced disease. Therefore, it is vital that screening programs and novel diagnostic tools are developed to increase lung cancer early detection. The development of a minimally invasive blood-based diagnostic tool would be ideal as a first-line screening procedure. An increasing number of studies are demonstrating that fluctuations of circulating miRNAs are associated to lung cancer. Recently, we described a serum circulating miRNA signature (miR-Test) diagnostic for asymptomatic, early stage, lung cancer, that was validated in a large cohort of individuals (N = 1115) enrolled in the lung cancer screening program COSMOS (Continuous Observation of SMOking Subjects). However, the transfer to the clinic of a blood test based on circ-miRNAs requires the establishment of standardized operating procedures (SOPs), working instructions and guidelines for all pre-analytical and analytical procedures. We identified possible sources of variability affecting circulating miRNAs, analyzed their impact on the miR-Test performance, and defined a standardized protocol to optimize miR-Test application. Analysis of all possible technical and biological variation affecting circ-miRNAs level, revealed two main sources of variability: one related to analytical procedures for miRNAs extraction and quantification, and the other due to pre-analytical conditions, on how samples are prepared. The extraction causes the main source of analytical imprecision. In conclusion, we identified an optimal protocol for the application of miR-Test for lung cancer early diagnosis. Citation Format: Francesca Montani, Matteo Marzi, Fabio Dezi, Elisa Dama, Rose Mary Carletti, Giulia Veronesi, Francesco Nicassio, Pier Paolo Di Fiore, Fabrizio Bianchi. Serum circulating miR–Test application: Standardized protocol for miR–Test clinical application. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1575. doi:10.1158/1538-7445.AM2015-1575
How Much Can the USA Reduce Health Care Costs by Reducing Smoking?
Authors: Wayne Hall, Chris Doran
Journal: PLoS Medicine (2016)

Cigarette smoking causes a wide variety of preventable diseases [1].Its prevalence has declined substantially since the first US Surgeon General's report (from 43% in 1965 to 18% today), but it remains a leading cause of preventable death in the United States, where it is responsible for more than 480,000 deaths per year, including nearly 42,000 deaths from secondhand smoke exposure.Declines in the prevalence of smoking among US adults (18 years of age and older) have slowed in recent years, and very large disparities in tobacco use remain across groups defined by race, ethnicity, educational level, and socioeconomic status and across regions of the country.Moreover, thousands of young people start smoking cigarettes every day, and estimates predict that if smoking continues at the current rate among US youth, 5.6 million of today's Americans younger than 18 years of age are expected to die prematurely from a smoking-related illness [1].The total economic cost of smoking in the US is estimated at more than $300 billion a year.This includes nearly $170 billion in direct medical care for adults and more than $156 billion in lost productivity due to premature death and exposure to secondhand smoke [2].To offset some of this cost, state governments collect $25.8 billion each year from tobacco taxes and legal settlements [1].How much can these costs be reduced by reducing smoking prevalence?In the current issue of PLOS Medicine, Light and Glantz quantify the extent to which lower rates of smoking in the US might translate into lower health care costs.They have estimated how much, on average, a 1% reduction in smoking prevalence in a US state was associated with reduced health costs in that state a year later.Light and Glantz used a regression analytic approach that took into account correlations between the time series and the effects of other differences between states that may influence state health care expenditure, e.g., population age structure, education, ethnic composition, and the prevalence of risky behavior (e.g., obesity, heavy alcohol use).They have also conducted sensitivity analyses to assess the effects on their results of unmeasured variables (e.g., black market tobacco), different ways of measuring smoking and different ways of statistically modelling the effects.Their results suggest that a 10% relative reduction in smoking prevalence between a state and the national average in one year was followed by an average $6.3 billion reduction (in 2012 dollars) in health care expenditure the following year.Consistent with this finding, the states with the most rigorous tobacco control policies had a much lower smoking prevalence and lower health care expenditures than states that did not have these policies.Like all modeling studies, this one has its limitations, as acknowledged by the authors.First, their analysis used aggregate state data on tobacco smoking prevalence and health care costs.We cannot use their results to infer the savings in treatment for individual smokers who
THU0592 Efficacy of Rehabilitation with TAI JI Quan on Disability, Quality of Life, Pain, Psychological Distress, Sleep in an Italian Cohort of Patients with Fibromyalgia Syndrome
Authors: A. Del Rosso, G. Paoletti, M. Calà, S. Maddali Bongi
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Fibromyalgia syndrome (FMS) is characterized by chronic widespread musculoskeletal pain, and muscle tenderness leading to disability, impaired quality of life (QoL), fatigue, and it is accompanied by sleep disorders and psychological distress. The Tai Ji Quan is a Chinese martial art that, integrating meditation, slow movements, deep breathing and relaxation, contributes to the distribution of Qi (vital breath) throughout the body. Some studies showed that Tai Ji Quan, in patients with rheumatic diseases and FMS, improved QoL, disability, and psychological distress (1-2). <h3>Objectives</h3> To evaluate the efficacy of Tai Ji Quan on disability, QoL, fatigue, sleep and psychological distress in an Italian cohort of FMS patients. <h3>Methods</h3> We enrolled 22 FMS patients (16 women and 6 men; age: 52,24±12,19 years; symptom onset: 8,2±5,39 years; diagnosis: 3,25±2,97 years). Eleven patients (Experimental Group) participated to a course of Tai Ji Quan Yang style of 17 lessons (1/week, 60 minutes each); 11 patients (Control Group) participated to an educational course about FMS (17 lessons; 1/week, 60 minutes each). At the enrollment (T0) and at the end of treatment (T1), all FMS patients were evaluated for disability, [Fibromyalgia Impact Questionnaire (FIQ) Health Assessment Questionnaire (HAQ)], QoL [Short-Form 36 (SF36)], fatigue [Functional Assessment of Chronic Illness-Fatigue (FACIT-F)], pain [Widespread Pain Index (WPI)], tenderness [Tender Points (TP)], Sleep Quality [Pittsburgh Sleep Quality Index (PSQI] and mood disorders [Hospital Anxiety and Depression Scale (HADS)]. <h3>Results</h3> At T0, parameters of FMS patients were similar in the 2 groups. A T1 versus T0, patients of the Experimental Group improved significantly in FIQ (P=0.019), SF36 Summary Physical Index (P=0.016), WPI (P=0.037), tender points (P=0.0035), PSQI total (P=0.044) and PSQI sleep duration (P=0.025) HADS (total score: P=0.015; anxiety subscale: P=0.028) (Table). Patients in the Control Group did not improve in any parameter. <h3>Conclusions</h3> In our FMS patients, Tai Ji Quan improved disability, QoL, psychological distress, sleep quality and pain. So. it may be regarded as an effective rehabilitation method for treating FMS patients. However, our results should be confirmed by further long-term studies, with follow-up evaluations, in larger populations. <h3>References</h3> Wang C.C, et al. Rheum Dis Clin North Am, 2011. Wang C.C, et al. N Engl J Med. 2010. <h3>Disclosure of Interest</h3> None declared
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): results from a subgroup of patient from the MITO-16A-MANGO OV2A phase 4 trial
Authors: S.C. Cecere, G. Daniele, D. Lorusso, G. Scambia, M.O. Nicoletto, E. Breda, N. Colombo, G. Artioli, B. Daniele, G. Lo Re, F. Raspagliesi, V. Chiappa, V. Salutari, G. Ferrandina, S. Greggi, A. Baldoni, M.C. Piccirillo, R. Fossati, F. Perrone, S. Pignata
Journal: Annals of Oncology (2015)
Prognostic value of microsatellite instability and intratumor activated cytotoxic lymphocytes in colon cancer
Authors: R Dolcetti, M Guidoboni, R Gafa, A Viel, C Doglioni, A Russo, A Santini, L Del Tin, E Macri, G Lanza, M Boiocchi
Journal: Annals of Oncology (2000)
冠動脈分岐部病変に対するTステント留置と小隆起(TAP)法の長期臨床転帰
Authors: Naganuma Toru, Latib Azeem, Basavarajaiah Sandeep, Chieffo Alaide, Hasegawa Tasuku, Kawaguchi Masanori, Takagi Kensuke, Nakamura Sunao, Colombo Antonio
Journal: Circulation (2013)
341TiP Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE
Authors: L. Licitra, C. Even, R. Haddad, M. Tahara, T. Goswami, A. Franks, U. Emeribe, A. Jarkowski, G. Melillo, R.L. Ferris
Journal: Annals of Oncology (2015)
Cell Susceptibility to the Cytotoxic Effect of the Carcinogens Dimethylnitrosamine and &lt;italic&gt;N&lt;/italic&gt;-Nitrosomethylurea
Authors: Eliezer Huberman, Martin Traut, Leo Sachs
Journal: JNCI Journal of the National Cancer Institute (1970)

Transformed hamster cells showed a resistance to the cytotoxic effect of dimethylnitrosamine (DMNA), whereas normal hamster cells were either susceptible or resistant. Hamster cells were still susceptible to the cytotoxic effect of DMN A when tested 4 months after the increase in cellular lifespan induced by DMNA. However, at a later time in culture there was a selection of resistant cells which showed a growth advantage in vitro and in vivo. A related nitroso compound N-nitrosomethylurea (NMU) was cytotoxic to normal and even more cytotoxic to transformed hamster cells. This difference with NMU seems related to the difference in the growth rate of the normal and transformed cells. The results indicate that susceptibility and resistance with different types of cells are found with DMNA, a carcinogenic nitroso compound which has to be converted enzymatically to the cytotoxic intermediate, while no such differential cytotoxicity is found with NMU, which seems to be nonenzymatically converted to the cytotoxic intermediate. DMNA, in contrast to benzo[a]pyrene (BP), was cytotoxic to normal human cells and, like BP, was not cytotoxic to transformed human cells. This difference suggests that the enzyme involved in the conversion of DMNA to a cytotoxic derivative is not identical with BP hydroxylase.
Phase II study of sorafenib (BAY 43–9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial
Authors: S. Welch, H. Hirte, R. J. Schilder, L. Elit, C. Townsley, L. Tinker, G. Pond, A. Afinec, J. J. Wright, A. M. Oza
Journal: Journal of Clinical Oncology (2006)

5084 Background: Sorafenib (BAY 43–9006; SOR) is a novel multi-targeted kinase inhibitor that targets the RAF/MEK/ERK signaling pathway, vascular endothelial growth factor (VEGF) receptor, platelet-derived growth factor receptor and flt-3. VEGFR is over-expressed in human ovarian tumors and this is associated with poor prognosis. Gemcitabine (GEM) is known to have single-agent activity in recurrent ovarian cancer (OC). A recent phase I study of GEM/SOR has demonstrated manageable toxicity and some objective responses in recurrent OC patients. We have designed a phase II trial to evaluate the efficacy of this novel combination in patients with recurrent OC. Methods: A two-stage, phase II clinical trial is underway for women with recurrent or refractory OC. Eligible patients may have received up to 2 prior lines of chemotherapy following recurrence, but must be GEM-naive. The treatment consists of SOR, 400mg PO bid continuously, in combination with GEM, IV weekly, 1000 mg/m 2 . Cycle 1 is an extended cycle of 7 weeks of GEM followed by a 1-week break. GEM is administered weekly for the first 3 weeks of each subsequent 4-week cycle. The primary endpoint is objective response rate, with response evaluated every 8 weeks. Results: 26 patients have been enrolled at 3 centers. 84 cycles have been administered (median 3; range 1–10). Median age was 57 (range: 37–77). 42% were ECOG PS 0 and 58% were PS 1. Of 18 patients evaluable for objective response, 1 patient had a confirmed PR by RECIST criteria and 5 patients had a confirmed PR by CA-125 criteria, yielding a combined RR of 33% in evaluable patients (RR by ITT = 23%). An additional 10 patients had SD. The median time to progression is 7.6 months (95% CI: 5.6-NA). 7 patients are inevaluable for objective response due to the following in cycle 1: withdrawal of consent (3), toxicity (2), and clinical PD (2). 1 patient on-study is yet to have a response evaluation. Grade 3 or 4 toxicities seen in more than 2 patients include: lymphopenia (8), thrombocytopenia (6), hypertension (3), hand-foot syndrome (3), pain (3), neutropenia (3) and hypokalemia (3). Conclusions: The preliminary results show encouraging activity with tolerable toxicity. This trial continues to accrue into a second stage. No significant financial relationships to disclose.
The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis
Authors: Pablo Gómez-del Arco, Eusebio Perdiguero, Paula Sofia Yunes-Leites, Rebeca Acín-Pérez, Miriam Zeini, Antonio Garcia-Gomez, Krishnamoorthy Sreenivasan, Miguel Jiménez-Alcázar, Jessica Segalés, Dolores López-Maderuelo, Beatriz Ornés, Luis Jesús Jiménez-Borreguero, Gaetano D’Amato, David Enshell-Seijffers, Bruce Morgan, Katia Georgopoulos, Abul B.M.M.K. Islam, Thomas Braun, José Luis de la Pompa, Johnny Kim, José A. Enriquez, Esteban Ballestar, Pura Muñoz-Cánoves, Juan Miguel Redondo
Journal: Cell Metabolism (2016)
Array-Based Integrative Analysis Of Epigenomic and Transcriptomic Alterations In CD71+ Bone Marrow Erythroprogenitor Cells From Patients With Myelodysplastic Syndromes
Authors: Maximilian Mossner, Axel Wilbertz, Stephanie Fey, Julia Obländer, Verena Nowak, Jovita Vogler, Florian Nolte, Ralf Bieber, Wolf-Karsten Hofmann, Mark Reinwald, Daniel Nowak
Journal: Blood (2013)
Macrophage colony-stimulating factor enhances the susceptibility of macrophages to infection by human immunodeficiency virus and reduces the activity of compounds that inhibit virus binding
Authors: A Bergamini, CF Perno, L Dini, M Capozzi, CD Pesce, L Ventura, L Cappannoli, L Falasca, G Milanese, R Calio
Journal: Blood (1994)
Tumor Necrosis Factor and the Tenacious α
Authors: Øystein Grimstad
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal